UroGen Pharma Ltd URGN
$27.65 −$4.08 (-12.86%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.65 0.00%
Open$31.15
Prev close$31.73
Day range$27.57 – $31.90
Volume2.40M
Market cap$1.36B
P/E (TTM)–
Dividend yield–
URGN Stock News
Headlines matching UroGen Pharma Ltd or the URGN ticker, most recent first.
- A Quick Look at Today's Ratings for UroGen Pharma Ltd(URGN.US), With a Forecast Between $48 to $75
- Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $60 Positive
- H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $75
- Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $42 Positive
- TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $50 Positive
- Goldman Sachs Maintains UroGen Pharma Ltd(URGN.US) With Hold Rating, Raises Target Price to $44 Positive
- Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $50 Positive
- H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $45
- TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35
- Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $40 Positive
- Urogen Pharma (URGN) Receives a Buy From H.C. Wainwright
- Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
- Ladenburg Thalmann Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $43
- H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $45 Positive
- H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
No comments yet — be the first to weigh in on URGN.
Sign in to join the discussion.